Share Awards to Executive Directors

Eco Animal Health Group PLC

22 March 2024

 

22 March 2024

ECO Animal Health Group plc

("ECO" or the "Company")

Share Awards to Executive Directors

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announced that on 21 March 2024, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan (the "LTIP") over 176,652 ordinary shares in the Company (representing approximately 0.26 percent of the Company's issued share capital) to Executive Directors listed below.

Name	Position	Number of Share Awards
David Hallas	Chief Executive Officer	101,403
Chris Wilks	Chief Financial Officer	75,249

These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three year vesting period. Further details on the LTIP can be found in the Company's 2022 Annual Report.

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899 Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970 Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	David Hallas
2.	Reason for the notification
a.	Position/status	Chief Executive Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP70B55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Award of nominal cost conditional share awards under the Company's LTIP.
c.	Price(s) and volume(s)	Price(s) Volume(s) 5p 101,403
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	21 March 2024
f.	Place of the transaction	Outside a trading venue.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Chris Wilks
2.	Reason for the notification
a.	Position/status	Chief Financial Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP70B55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Award of nominal cost conditional share awards under the Company's LTIP.
c.	Price(s) and volume(s)	Price(s) Volume(s) 5p 75,249
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	21 March 2024
f.	Place of the transaction	Outside a trading venue.

 

END